SK-02
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Pre-clinicalActive
Key Facts
Indication
Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Phase
Pre-clinical
Status
Active
Company
About Synerkine Pharma
Synerkine Pharma is an early-stage biotech developing a proprietary platform of cytokine fusion proteins, termed Synerkines, designed to treat conditions with high unmet medical need, particularly chronic pain. Its lead asset, SK-01, has received European Orphan Drug Designation for Complex Regional Pain Syndrome (CRPS), and a second program, SK-02, targets Chemotherapy-Induced Peripheral Neuropathy (CIPN). The company is backed by experienced life science investors like Flerie Invest and Thuja Capital and operates with a lean, experienced management team.
View full company profileTherapeutic Areas
Other Chemotherapy-Induced Peripheral Neuropathy (CIPN) Drugs
| Drug | Company | Phase |
|---|---|---|
| BXQ-350 | Bexion Pharmaceuticals | Proof of Concept |
| Chemotherapy Adverse Events | NETRI | Pre-clinical |